Medical Research

At CAF, Medical Research is Key

Medical researchers who are interested in initiating a thalassemia-related project or who have an existing project that requires additional funding: The Cooley’s Anemia Foundation may be just what you need.

CAF has a decades-long history of supporting innovative and important research in thalassemia. Our established and respected Medical Fellowship program has funded numerous early career individuals who have continued to stay in the thalassemia field and make important contributions to the scientific and clinical study of thalassemia.

Our Support for Ongoing Clinical Research in Thalassemia Grants and Clinical Trials in Thalassemia Cell and Gene Therapy Grants are aggressively pushing forward the understanding of issues of concern to the growing thalassemia population and helping to propel advances in areas of primary importance.

bluebird bio Announces First Patient Transplanted in Phase 1/2 HGB-205 Study for the Treatment of Beta-Thalassemia and Sickle Cell Anemia

December 2, 2013 – bluebird bio, Inc. today announced that the first subject with beta-thalassemia major has been enrolled in its phase 1/2 HGB-205 study in France and has undergone infusion with bluebird bio’s LentiGlobin drug product in an autologous hematopoietic stem cell transplantation. “We believe gene therapy represents a potentially new and exciting treatment […]

Read more

CAF Accepting Research Grant and Fellowship Applications

October 21, 2013 – The Cooley’s Anemia Foundation is accepting applications for medical research grants and fellowships in areas related to thalassemia.  Details are as follows: SUPPORT FOR ONGOING CLINICAL RESEARCH IN THALASSEMIA The Cooley’s Anemia Foundation invites national and international applications for 2014-2015 grants to support ongoing clinical research projects in Thalassemia. The goal […]

Read more

CAF Funds $375,000 in Important Thalassemia Research Areas

July 15, 2013 – What would motivate a person with thalassemia to make changes to improve adherence to therapy?  Can metabolic substances in a person with thalassemia give a clue to how iron is loading in his/her heart?  Would moving the fetal hemoglobin gene cause it to create more fetal hemoglobin? These are just some […]

Read more

American Heart Association Releases Statement on Cardiac Dysfunction in Thalassemia Major

June 20, 2013 – The American Heart Association (AHA)  has released a consensus statement on “Cardiovascular Function and Treatment in Beta-Thalassemia Major.” Published online in the AHA journal Circulation, the document states in part that “central to early identification of cardiac iron overload in TM (thalassemia major) is the estimation of cardiac iron by cardiac […]

Read more

June 15 is Deadline for International Thalassemia Award Applications

May 1, 2013 – The deadline for applying for one of the 2013 Sultan Bin Khalifa International Thalassemia Awards,established by H.H. Dr. Sheikh Sultan Bin Khalifa Al Nahyan in partnership with the Thalassaemia International Federation, is June 15. The Awards are intended to recognize outstanding contributions in thalassemia by medical professionals, researchers, patients, parents and organizations.  […]

Read more

Support for Ongoing Clinical Research in Thalassemia

The Cooley’s Anemia Foundation invites national and international applicants to apply for grants to support ongoing clinical research projects in thalassemia. The goal of this initiative is to support investigators from all disciplines and backgrounds (MD, RN, PhD, MPH, MSW or other disciplines) with their ongoing clinical projects to address one or more of the […]

Read more

Clinical Trials in Thalassemia Cell and Gene Therapy Grants

The Cooley’s Anemia Foundation invites national and international applicants to apply for grants to facilitate clinical trials in Cell and Gene Therapy to advance a cure for thalassemia.   The purpose of this initiative is to speed the application of recent translational advances in cell and gene therapy to clinical trials. Both phase I (safety) and […]

Read more

Acceleron Developing Thalassemia Treatments

January 28, 2013 – Acceleron, a biopharmaceutical company based in Cambridge, Massahusetts, in collaboration with Summit, New Jersey-based pharmaceutical partner Celgene Corporation, is developing two programs, sotatercept (formerly called ACE-011) and ACE-536, for the treatment of beta-thalassemia. Sotatercept and ACE-536 are biologic drugs that increase hemoglobin and red blood cells levels by promoting the maturation […]

Read more

Exjade Approved for Use in Non-Transfusion-Dependent Thalassemia

January 23, 2013 – From an FDA press release: The U.S. Food and Drug Administration today expanded the approved use of Exjade (deferasirox) to treat patients ages 10 years and older who have chronic iron overload resulting from a genetic blood disorder called non-transfusion-dependent thalassemia (NTDT). NTDT is a milder form of thalassemia that does […]

Read more

U.S.-Based Gene Therapy Study Begins Treating Participants

January 10, 2013 – CAF has learned that the first U.S.-based clinical trial in gene therapy for beta-thalassemia has begun treating trial participants.   The Phase 1 study, the official title of which is “ß-Thalassemia Major With Autologous CD34+ Hematopoietic Progenitor Cells Transduced With TNS9.3.55 a Lentiviral Vector Encoding the Normal Human ß-Globin Gene,” is […]

Read more

Secured By miniOrange